Diabetes Drugs May Help Some People Avoid Knee Surgery—But Won't Stop the Pain

A large study from Shanghai tracking 1,807 patients suggests that a popular type of diabetes medication might reduce the need for knee surgery. The researchers compared 233 people taking drugs called GLP-1 agonists (specifically liraglutide and semaglutide) with 1,574 people who didn't take these drugs. All had both knee arthritis and type 2 diabetes. Those on the diabetes drugs had fewer knee surgeries over time.

This matters because doctors are increasingly curious: could medications designed to treat diabetes also help with other health problems? In this case, the question is whether these drugs—which have become expensive and somewhat controversial—might ease the burden of knee arthritis, a condition that affects millions of people and often leads to expensive joint replacement surgery.

But here's the catch: the same research showing fewer surgeries also reveals something unexpected. These medications don't seem to reduce the pain that arthritis patients feel. This points to something important about how disease actually works in the human body—sometimes slowing damage and reducing pain are two different things.

Two Different Outcomes: Surgery Versus Pain

The Shanghai study found something puzzling. People taking GLP-1 drugs needed less surgery, but their knee pain didn't improve more than it did for people not taking the drugs.

A controlled trial examined whether liraglutide (one of these drugs) could relieve knee pain in overweight people with arthritis. After one year, patients taking the drug reported the same amount of pain as those taking a placebo—a dummy pill with no active ingredient.

Why the difference? When doctors decide to perform knee replacement surgery, they consider multiple factors: how much the joint has physically deteriorated, whether you can still do daily activities, and your overall quality of life. Pain alone doesn't always trigger surgery. If weight loss reduces stress on the joint and improves your body's overall condition, you may avoid surgery even if your pain level stays the same.

This distinction is worth understanding. The medications may be slowing damage to the joint structure, which is different from making the pain go away.

Using These Drugs Before Surgery

Researchers at Yale found another potential use: preparing patients for surgery. In a study of people with diabetes undergoing knee replacement, three months of semaglutide treatment before surgery led to better outcomes.

This fits into a broader surgical trend called "prehabilitation"—getting your body in the best possible condition before an elective procedure to speed recovery. If GLP-1 drugs improve your glucose control and overall metabolic health, they could make surgery safer and recovery smoother.

The Cost Question

These medications are expensive—often more than $1,000 per month. Health insurance companies and hospitals are increasingly asking whether that cost is worth it.

A typical knee replacement surgery costs between $30,000 and $50,000. If GLP-1 drugs help people avoid surgery, the math might work out: the cost of medication for several months could be less than the cost of surgery. But the picture gets complicated. These drugs also reduce heart disease risk and cause weight loss, which affects other health conditions, not just arthritis. Calculating whether they're worth the cost requires tracking multiple health benefits at once.

The larger economic picture here is worth considering. Healthcare systems are strained, and expensive medications that might prevent even some surgeries have serious budget implications for hospitals and insurance companies.

Weight Loss May Be the Real Mechanism

Weight is central to knee arthritis. Medical guidelines consistently recommend weight loss as a core treatment for overweight people with arthritis. The biomechanics are straightforward: every kilogram of weight you lose reduces the force pressing on your knee joints by roughly four kilograms during activities like walking.

GLP-1 agonists cause substantial weight loss—typically 10 to 15 percent of body weight—by suppressing appetite and slowing how fast food leaves your stomach. This weight loss directly reduces stress on joints and lowers inflammation in the body.

Think of it this way: the medication works partly like a very effective diet aid. The joint benefit may come primarily from carrying less weight, not from the drug directly protecting cartilage.

This observation connects to a broader trend in medicine. Drugs developed for one purpose sometimes help with unexpected conditions. Statins were originally designed to lower cholesterol but later found to reduce heart attack and stroke risk. GLP-1 agonists were designed for diabetes but are now used for weight loss. The question is whether these medications will follow a similar path in arthritis treatment or remain mainly as weight-loss aids that happen to have other benefits.

What This Means for Patients and Doctors

The emerging evidence suggests that for people with both diabetes and arthritis, GLP-1 agonists may lower the risk of needing surgery. This is useful information. However, doctors need to be clear with patients: these drugs may help you avoid surgery down the road, but they probably won't reduce your pain immediately.

That distinction matters because many arthritis patients want pain relief now. Managing expectations is part of good medical practice.

The Yale protocol—using three months of medication before scheduled surgery—offers a concrete way doctors could actually use this information. Most orthopedic surgeries are scheduled weeks or months in advance, so there's room to fit in a three-month treatment window.

The economic puzzle remains unsolved. Hospital systems need better data on whether the high cost of these medications offsets the cost of surgery avoided. That's especially true when you account for all the other benefits—better diabetes control, lower heart disease risk—that don't show up directly in arthritis treatment but affect patients' overall health.

What We Still Don't Know

The Shanghai study is observational—meaning researchers watched what happened but didn't randomly assign some people to take the drug and others not to. That design can't prove that the medication caused fewer surgeries. Someone needs to conduct a carefully controlled trial with surgery as the main outcome measured, but that would take years because arthritis progresses slowly.

No one fully understands how these drugs might protect joints. Do they work directly on cells in the joint? Or do all the benefits come from weight loss and better blood sugar control? The answer matters because it could change how doctors dose the medication and which patients would benefit most.

Most research has focused on the knee in people with diabetes. The hip joint works differently mechanically, and non-diabetic people might respond differently to these drugs. Answering those questions requires additional study.

What Comes Next

We're entering a new phase of how doctors treat multiple chronic conditions at once—diabetes, arthritis, heart disease—together rather than separately. The Shanghai findings offer useful information, but they also raise new questions about who should take these drugs, whether they actually work better than just losing weight through diet and exercise, and how healthcare systems should decide what's worth the cost.

The evidence is still being written. For now, doctors treating patients with both diabetes and arthritis have data supporting GLP-1 agonist use to reduce surgery risk—even if pain relief isn't part of the benefit.